Defining SARS-CoV-2 Bivalent Vaccines and Optimizing Protection Through Vaccination

Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Jacinda Abdul-Mutakabbir, PharmD; and Rodney E. Rohde, PhD, MS, SM(ASCP)CM, SVCM, MBCM, FACSc; review what encompasses a bivalent vaccine and give their perspective on how to communicate the role of the vaccine in optimizing protection for patients.

Related Videos
Related Content

Young People’s Risk of Death After COVID-19 Vaccination or Infection

March 30th 2023

Vaccine Race: The Pfizer Vaccine with William Schaffner, MD

November 16th 2020

Negative Expectations of COVID-19 Vaccines Led to More Adverse Events After Vaccination

March 28th 2023

COVID-19 Vaccine Race: FDA Advisory Committee Meeting with Donald Alcendor, PhD

October 26th 2020

FDA Committee Endorses Full Approval of Paxlovid for COVID-19 Treatment

March 16th 2023

Pfizer-BioNTech Omicron Bivalent Booster Receives FDA Emergency Use Authorization for Children Under 5

March 15th 2023

Young People’s Risk of Death After COVID-19 Vaccination or Infection

March 30th 2023

Vaccine Race: The Pfizer Vaccine with William Schaffner, MD

November 16th 2020

Negative Expectations of COVID-19 Vaccines Led to More Adverse Events After Vaccination

March 28th 2023

COVID-19 Vaccine Race: FDA Advisory Committee Meeting with Donald Alcendor, PhD

October 26th 2020

FDA Committee Endorses Full Approval of Paxlovid for COVID-19 Treatment

March 16th 2023

Pfizer-BioNTech Omicron Bivalent Booster Receives FDA Emergency Use Authorization for Children Under 5

March 15th 2023

Young People’s Risk of Death After COVID-19 Vaccination or Infection

March 30th 2023

Vaccine Race: The Pfizer Vaccine with William Schaffner, MD

November 16th 2020

Negative Expectations of COVID-19 Vaccines Led to More Adverse Events After Vaccination

March 28th 2023

COVID-19 Vaccine Race: FDA Advisory Committee Meeting with Donald Alcendor, PhD

October 26th 2020

FDA Committee Endorses Full Approval of Paxlovid for COVID-19 Treatment

March 16th 2023

Pfizer-BioNTech Omicron Bivalent Booster Receives FDA Emergency Use Authorization for Children Under 5

March 15th 2023
© 2023 MJH Life Sciences

All rights reserved.